Literature DB >> 10217608

Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents.

A Mark1, R M Carlsson, M Granström.   

Abstract

The importance of the injection technique in booster vaccination was investigated in an open randomized study with 252 10-year-old Swedish school-children receiving routine DT vaccination either by subcutaneous or by intramuscular route in the upper arm. The adolescents had previously been primed with DT vaccine at 3, 5 and 12 months of age. Adverse reactions, monitored for 2 weeks, showed the same low rates for systemic reactions in both groups, while the intramuscular administration gave significantly less redness (p < 0.001), swelling (p < 0.001), itching (p < 0.01) and pain (p < 0.05). These reactions were also of shorter duration (p < 0.01 to p < 0.001). Girls were found to have more pain and itching than boys (p < 0.001). No significant differences in antibody responses between the two administration routes were found in the 99 samples drawn 2 weeks after the booster. However, girls were found to have a lower response to diphtheria toxoid than boys (p = 0.009). Local reactions to a booster can thus be significantly reduced by choice of injection technique, which may be necessary if increased dosages and/or further valences are to be given to adolescents and adults.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217608     DOI: 10.1016/s0264-410x(98)00410-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Needle length and incidence of local reactions to immunisation. How quickly can research change practice?

Authors:  J Platt
Journal:  BMJ       Date:  2001-02-24

Review 2.  Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.

Authors:  Anna Taddio; Mary Appleton; Robert Bortolussi; Christine Chambers; Vinita Dubey; Scott Halperin; Anita Hanrahan; Moshe Ipp; Donna Lockett; Noni MacDonald; Deana Midmer; Patricia Mousmanis; Valerie Palda; Karen Pielak; Rebecca Pillai Riddell; Michael Rieder; Jeffrey Scott; Vibhuti Shah
Journal:  CMAJ       Date:  2010-11-22       Impact factor: 8.262

Review 3.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

4.  Size of the needle for infant vaccination.

Authors:  Richard Kent Zimmerman
Journal:  BMJ       Date:  2006-09-16

Review 5.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

6.  Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial.

Authors:  Linda Diggle; Jonathan J Deeks; Andrew J Pollard
Journal:  BMJ       Date:  2006-08-04

7.  Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.

Authors:  Rui Kuai; Xiaoqi Sun; Wenmin Yuan; Yao Xu; Anna Schwendeman; James J Moon
Journal:  Bioconjug Chem       Date:  2018-02-27       Impact factor: 4.774

8.  BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.

Authors:  Sangeeta Tiwari; Taru S Dutt; Bing Chen; Mei Chen; John Kim; Annie Zhi Dai; Regy Lukose; Crystal Shanley; Amy Fox; Burton R Karger; Steven A Porcelli; John Chan; Brendan K Podell; Andres Obregon-Henao; Ian M Orme; William R Jacobs; Marcela Henao-Tamayo
Journal:  Vaccine       Date:  2020-09-23       Impact factor: 3.641

9.  Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity.

Authors:  Sebastian Ols; Lifei Yang; Elizabeth A Thompson; Pradeepa Pushparaj; Karen Tran; Frank Liang; Ang Lin; Bengt Eriksson; Gunilla B Karlsson Hedestam; Richard T Wyatt; Karin Loré
Journal:  Cell Rep       Date:  2020-03-24       Impact factor: 9.423

10.  Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Authors:  Christopher S Morello; Kimberly A Kraynyak; Michael S Levinson; Zhijiang Chen; Kuo-Fen Lee; Deborah H Spector
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.